GODAVARI DRUGS LIMITED

CIN NO.L25230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND QUARTER ENDED SEPTEMBER 30, 2017

(Rs. In Lakhs)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2017 (Unaudited)	30.06.2017 (Unaudited)	30.09.2016 (Unaudited)	30.09.2017 (Unaudited)	30.09.2016 (Unaudited)	31.03.2017 (Audited)
1	**Revenue from operations**	**1763.34**	1196.52	2060.39	2959.86	4305.19	7559.82
2	Other Income	**1.48**	19.28	17.35	20.76	17.80	80.23
3	**Total Revenue from operations (1+2)**	**1764.82**	**1215.80**	**2077.74**	**2980.62**	**4322.99**	**7640.05**
4	**Expenses**			17.00			
	(a) Cost of materials consumed	**736.86**	1281.67	1583.57	2018.53	3527.98	6325.28
	(b) Changes in inventories of finished goods & work-in-progress	**682.04**	-441.31	68.05	240.73	-69.40	-431.28
	(c) Employee benefits expense	**66.62**	62.63	60.21	129.25	116.89	237.91
	(d) Depreciation & amortization expense	**23.97**	23.77	15.72	47.74	30.81	80.68
	(e) Finance Costs	**58.84**	54.86	60.09	113.70	115.21	250.94
	(f) Other Expenses	**182.43**	224.99	229.91	407.42	475.63	905.73
	Total expenses	**1750.76**	**1206.61**	**2017.55**	**2957.37**	**4197.12**	**7369.26**
5	**Profit before exceptional Items and tax (3-4)**	**14.06**	**9.19**	**60.19**	**23.25**	**125.87**	**270.79**
6	Exceptional items	**0.00**	0.00	0.00	0.00		
7	**Profit before Tax (5-6)**	**14.06**	**9.19**	**60.19**	**23.25**	**125.87**	**270.79**
8	**Tax expense**						
	(a) Current Tax	**3.28**	1.84	19.92	5.12	41.60	55.40
	(b) MAT credit entitlement						-5.01
	(c) Deferred Tax	**3.24**	-1.56		1.68		39.48
	Total Tax Expenses	**6.52**	**0.28**	**19.92**	**6.80**	**41.60**	**89.87**
9	**Net Profit for the period (7-8)**	**7.54**	**8.91**	**40.27**	**16.45**	**84.27**	**180.92**
10	**Other Comprehensive Income**						
	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-	-
11	**Total Comprehensive Income (9+10)**	**7.54**	**8.91**	**40.27**	**16.45**	**84.27**	**180.92**
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	**753.05**	753.05	753.05	753.05	753.05	753.05
13	Other Equity						
14	**Earnings per share (of Rs.10/- each) (not annualized)**						

For V. SRIDHAR & CO
CHARTERED ACCOUNTANTS
VEMULAPATI SRIDHAR
PROPRIETOR

GODAVARI DRUGS SEC'BAD

For GODAVARI DRUGS LTD.

K. K. Jain

Director

(Rs. In Lakhs)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2017 (Unaudited)	30.06.2017 (Unaudited)	30.09.2016 (Unaudited)	30.09.2017 (Unaudited)	30.09.2016 (Unaudited)	31.03.2017 (Audited)
	(a) Basic	0.10	0.12	0.53	0.22	1.12	2.40
	(b) Diluted	0.10	0.12	0.53	0.22	1.12	2.40

Note:

1. The above results , as revicwed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 10th November 2017.
2. The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
3. The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33(3)© of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.
4. Segment wise reporting as applicable under IND AS – 108 for the quarter ended 30th September, 2017 has given separately.
5. The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.
6. As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
7. Income from operations are disclosed net of excise duty and net of VAT/CST as per clarification issued by SEBI Dated 20.09.2016 upto quarter ended 30.06.2017 and for the quarter ended 30.09.2017 is net of GST.
8. Corresponding figures in previsous year / period have been regrouped wherever considered necessary.

For V. SRIDHAR & CO.
CHARTERED ACCOUNTANTS
VEMULAPATI SRIDHAR
PROPRIETOR

For GODAVARI DRUGS LTD.

K. K. Jain
Director

GODAVARI DRUGS LTD. SEC'BAD

Godavari Drugs Limited
Balance Sheet As at September 30, 2017

Rupees

Particulars	Note No.	As at 30 Sept, 2017	As at March 31, 2017
ASSETS			
1. Non - current assets			
a. Property, Plant and Equipment	1	**12,29,22,411**	12,76,96,883
b. Tangible Assets		**-**	-
c. Capital Work in Progress		**2,31,01,561**	11,53,187
d. Goodwill		**-**	-
e. Other Intangible assets		**-**	-
f. Intangible assets under development		**-**	-
g. Biological Assets other than bearer plants		**-**	-
h. Financial Assets			
(i) Investments	2	**1,000**	1,000
(ii) Trade Receivables		**-**	-
(iii) Loans	3	**26,54,421**	18,66,798
(iv) Others (to be secified)		**-**	-
i. Deferred tax assets (net)		**-**	-
j. Other non-current assets		**-**	-
2. Current assets			
(a) Inventories	4	**9,96,56,146**	11,32,41,532
(b) Financial Assets			
(i) Investments		**-**	
(ii) Trade Receivables	5	**27,25,39,438**	24,17,10,110
(iii) Cash and cash equivalents	6	**2,30,57,429**	88,27,876
(iv) Bank balances other than (iii) above			
(v) Loans	7	**6,34,53,745**	6,22,70,975
(vi) Others (to be specified)		**-**	
(c) Current Tax Assets (Net)		**-**	-
(d) Other current assets	8	**95,402**	2,34,169
Total Assets		**60,74,81,553**	55,70,02,530
EQUITY AND LIABILITIES			
EQUITY			
(a) Equity Share capital	9	**7,53,05,000**	7,53,05,000
(b) Other Equity	10	**8,85,34,452**	8,68,89,608
LIABILITIES			
1. Non -current liabilities			
(a) Financial Liabilities			
(i) Borrowings	11	**7,81,89,544**	4,38,57,183
(ii) Trade payables		**-**	-
(iii) Other financial liabilities (other than those specified in item (b), to be specified)		**-**	-
(b) Provisions	12	**42,91,418**	39,11,810
(c) Deferred tax liabilities (Net)	13	**1,22,11,485**	1,20,43,485
(d) Other non-current liabilities		**-**	-
2. Current liabilities			
(a) Financial Liabilities			
(i) Borrowings	14	**10,89,24,767**	11,33,34,748
(ii) Trade payables	15	**22,62,00,649**	20,05,96,756
(iii) Other financial liabilities (other than those specified in item (c)	16	**76,30,179**	2,01,58,384
(b) Other current liabilities		**-**	-
(c) Provisions		**-**	-
(d) Current Tax Liabilities (Net)	17	**61,94,059**	9,05,556
Total Equity and Liabilities		**60,74,81,553**	55,70,02,530

GODAVARI DRUGS LTD. SECBAD

For GODAVARI DRUGS LTD.

K. K. Jain

Director